Mostrar el registro sencillo del ítem

dc.contributor.authorRigo, Graziela de Vargaspt_BR
dc.contributor.authorFrank, Luiza Abrahãopt_BR
dc.contributor.authorGalego, Giulia Bongiornipt_BR
dc.contributor.authorSantos, André Luis Souza dospt_BR
dc.contributor.authorTasca, Tianapt_BR
dc.date.accessioned2023-06-17T03:37:00Zpt_BR
dc.date.issued2022pt_BR
dc.identifier.issn2674-0710pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/259095pt_BR
dc.description.abstractThe multistep translational science behind new drugs comprehends the entire process through laboratory, clinical, and community observations turned into health interventions. The development of new drug options from discovering targets and leading compounds in basic research for implementing therapeutic guidelines contributes to the emergence of health policies essential for infection control. This review updates the translational research in the scenario of the most common non-viral sexually transmitted infection (STI), trichomoniasis. Paradoxically to its high occurrence, it is considered neglected since notification is not mandatory. It turns into a stable disease with health complications, and receives little emphasis from public health programs to control STI. Although related to curable STIs, the current drugs, metronidazole and tinidazole, present therapeutic failures. The need for new options to treat trichomoniasis is established by basic research studies and patents revealing novel synthetic compounds and natural products presenting anti-Trichomonas vaginalis activities, mainly based on in vitro findings. Clinical trials are still focused on new routes of administration for conventional drugs. In addition, nanotechnology approaches are in their infancy, shedding light on potential possibilities for creating more effective, targeted, and safe delivery systems. Overall, the novel proposed approaches need, in addition to pharmaceutical development and efficacy assessments, to ensure that the quality requirements for their use as medicines are met. It is essential to overcome these issues to cross the “Death Valley” of drug discovery and to advance in the translational science criteria in the trichomoniasis drug development field.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofVenereology. Basel. Vol. 1, n. 1 (2022), p. 47-80pt_BR
dc.rightsOpen Accessen
dc.subjectTrichomoniasisen
dc.subjectTricomoníasept_BR
dc.subjectCiência translacional biomédicapt_BR
dc.subjectTranslational scienceen
dc.subjectBasic researchen
dc.subjectProdutos biológicospt_BR
dc.subjectNatural productsen
dc.subjectNanotecnologiapt_BR
dc.subjectNanotechnologyen
dc.subjectPatentsen
dc.subjectClinical trialsen
dc.titleNovel treatment approaches to combat trichomoniasis, a neglected and sexually transmitted infection caused by trichomonas vaginalis : translational perspectivespt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001163565pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem